This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NovaBay Pharmaceuticals Reports Fourth Quarter Financial Results And 2013 Clinical And Business Update

Well Positioned in 2013 with Three Phase 2b Clinical Trials for Conjunctivitis, Impetigo and UCBE Advancing

EMERYVILLE, Calif., March 14, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global topical, non-systemic anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today gave a fourth quarter financial and clinical update and outlook for 2013.

Dr. Ron Najafi, Chairman and CEO, remarked, "We are particularly excited about 2013 as the enrollment in our three auriclosene trials continues to advance and we move towards data from these three trials. Our global viral conjunctivitis trial, BAYnovation, is underway in India as of January and recruitment efforts are continuing to ramp. The impetigo trial being implemented by our partner Galderma expanded enrollment to South Africa in February. The urinary catheter blockage and encrustation (UCBE) trial continues to enroll at a steady pace."

Dr. Najafi concluded, "Over the past year, we have achieved several significant development milestones and strengthened our balance sheet. We brought in approximately $7 million in capital in December that provided the resources to advance our three clinical trials and to conduct a Phase 2 study of auriclosene as a treatment for bacterial conjunctivitis, facilitating our ultimate goal of one product to treat both viral and bacterial conjunctivitis."

Fourth Quarter and Full Year Financial Results

As of December 31, 2012, cash, cash equivalents and short-term investments totaled $16.9 million, compared to $14.1 million at the end of 2011, representing a full-year net cash increase of approximately $2.7 million, or 19.3%. The cash increase reflects cash received from the company's R&D partners as milestone payments, the December 2012 public offering of common stock and warrants, and an additional $2.5 million of financing from a private placement of common stock and warrants.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs